​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte stock forecast is as follows: an average price target of $90.11 (represents a 32.56% upside from INCY’s last price of $67.97) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

INCY Price Target

The average price target for Incyte (INCY) is $90.11 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $48.00. This represents a potential 32.56% upside from INCY's last price of $67.97.

INCY Analyst Ratings

Buy

According to 21 Wall Street analysts, Incyte's rating consensus is 'Buy'. The analyst rating breakdown for INCY stock is 0 'Strong Buy' (0.00%), 14 'Buy' (66.67%), 7 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Incyte Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Aaron KesslerSeaport Global$200.00$73.00173.97%194.23%
Oct 30, 2024Jay OlsonOppenheimer$82.00$73.6011.41%20.63%
Oct 30, 2024David LebowitzCitigroup$97.00$73.6031.79%42.70%
Oct 29, 2024Kelly ShiJefferies$84.00$73.6014.13%23.57%
Oct 29, 2024Tazeen AhmadBank of America Securities$90.00$73.6022.28%32.40%
Sep 30, 2024Andy ChenWolfe Research$84.00$66.1027.08%23.57%
Sep 16, 2024Tazeen AhmadBank of America Securities$68.00$63.566.99%0.04%
Sep 16, 2024Salveen RichterGoldman Sachs$60.00$63.56-5.60%-11.73%
Aug 18, 2024David LebowitzCitigroup$92.00$62.1648.01%35.34%
Jul 31, 2024Brian AbrahamsRBC Capital$66.00$65.700.46%-2.91%
Jul 26, 2024Jay OlsonOppenheimer$81.00$68.5718.13%19.16%
Jul 02, 2024Evan SeigermanBMO Capital$48.00$60.87-21.14%-29.39%
May 23, 2024James ShinDeutsche Bank$55.00$58.20-5.50%-19.09%
Apr 30, 2024Evan David SeigermanBMO Capital$52.00$52.05-0.10%-23.50%
Apr 25, 2024Jasper HellwegArgus Research$70.00$50.4838.67%2.98%
Feb 08, 2023Cowen & Co.$100.00$80.3824.42%47.11%
Jan 03, 2023Wells Fargo$75.00$79.73-5.94%10.33%
Aug 15, 2022Jay OlsonOppenheimer$98.00$73.9932.45%44.17%
Jul 20, 2022Leerink Partners$63.00$81.36-22.57%-7.32%
Apr 20, 2022Morgan Stanley$76.00$78.94-3.72%11.81%
Feb 08, 2022Evan SeigermanBMO Capital$75.00$70.077.04%10.33%
Jan 03, 2022Michael SchmidtGuggenheim$104.00$73.9740.60%53.00%
Nov 24, 2021Salveen RichterGoldman Sachs$136.00$66.74103.78%100.07%
Nov 03, 2021Jay OlsonOppenheimer$109.00$66.7963.20%60.35%
Oct 15, 2021Alethia YoungCantor Fitzgerald$79.00$65.5620.50%16.22%
Sep 23, 2021Aydin HuseynovLadenburg Thalmann & Co.$89.00$69.7827.54%30.93%

The latest Incyte stock forecast, released on Oct 30, 2024 by Aaron Kessler from Seaport Global, set a price target of $200.00, which represents a 173.97% increase from the stock price at the time of the forecast ($73.00), and a 194.23% increase from INCY last price ($67.97).

Incyte Price Target by Period

1M3M12M
# Anlaysts-615
Avg Price Target-$106.17$81.93
Last Closing Price$67.97$67.97$67.97
Upside/Downside-100.00%56.19%20.53%

In the current month, the average price target of Incyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Incyte's last price of $67.97. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2024OppenheimerOutperformOutperformHold
Nov 19, 2024BMO CapitalUnderperformUnderperformHold
Oct 30, 2024Seaport GlobalBuyUpgrade
Oct 30, 2024RBC CapitalSector PerformSector PerformHold
Oct 30, 2024BMO CapitalUnderperformUnderperformHold
Oct 30, 2024CitigroupBuyBuyHold
Oct 29, 2024JefferiesBuyBuyHold
Oct 29, 2024Bank of America SecuritiesNeutralBuyUpgrade
Oct 23, 2024Wells FargoSector PerformSector PerformHold
Oct 22, 2024OppenheimerOutperformOutperformHold
Oct 01, 2024RBC CapitalSector PerformSector PerformHold
Oct 01, 2024OppenheimerUnderperformUnderperformHold
Sep 30, 2024Wolfe ResearchOutperformInitialise
Sep 16, 2024GuggenheimBuyBuyHold
Sep 16, 2024Cowen & Co.BuyBuyHold
Sep 16, 2024Bank of America SecuritiesNeutralNeutralHold
Sep 16, 2024Goldman SachsNeutralNeutralHold
Sep 03, 2024RBC CapitalSector PerformSector PerformHold
Aug 15, 2024BMO CapitalUnderperformUnderperformHold
Jul 31, 2024BarclaysOverweightOverweightHold
Jul 31, 2024RBC CapitalSector PerformSector PerformHold
Jul 31, 2024CitigroupBuyBuyHold
Jul 26, 2024OppenheimerOutperformOutperformHold
Jul 02, 2024BMO CapitalMarket PerformUnderperformDowngrade
Jun 18, 2024RBC CapitalMarket PerformMarket PerformHold
May 23, 2024OppenheimerUnderperformUnderperformHold
May 23, 2024RBC CapitalMarket PerformMarket PerformHold
May 23, 2024Deutsche BankHoldInitialise
May 01, 2024Cowen & Co.BuyBuyHold
Apr 30, 2024BMO CapitalMarket PerformMarket PerformHold
Apr 23, 2024Cantor FitzgeraldNeutralInitialise
Mar 12, 2024RBC CapitalSector PerformSector PerformHold
Feb 14, 2024Truist FinancialMarket OutperformMarket OutperformHold
Feb 14, 2024Mizuho SecuritiesUnderperformUnderperformHold
Dec 13, 2023Leerink PartnersOutperformUpgrade
Dec 04, 2023GuggenheimBuyUpgrade
Nov 21, 2023Goldman SachsBuyNeutralDowngrade
Nov 02, 2023Goldman SachsBuyBuyHold
Aug 01, 2023William BlairOutperformOutperformHold
Apr 10, 2023RBC CapitalSector PerformDowngrade
Mar 24, 2023SVB LeerinkUnderperformMarket PerformUpgrade
Feb 08, 2023Cowen & Co.OutperformOutperformHold
Feb 08, 2023Piper SandlerOverweightOverweightHold
Jan 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Aug 15, 2022OppenheimerOutperformOutperformHold
Jul 21, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Jul 20, 2022SVB LeerinkUnderperformUnderperformHold
Apr 26, 2022Zacks Investment ResearchHoldUpgrade

Incyte's last stock rating was published by Oppenheimer on Nov 19, 2024. The company gave INCY a "Outperform" rating, the same as its previous rate.

Incyte Financial Forecast

Incyte Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$919.02M$954.61M$808.67M$926.70M$823.30M$911.40M$733.24M$862.85M$812.99M$705.71M$604.72M$789.51M$620.64M$688.04M$568.51M$579.39M$551.58M
Avg Forecast$1.38B$1.36B$1.28B$1.11B$1.26B$1.19B$1.14B$1.00B$1.14B$1.08B$1.01B$921.89M$1.00B$963.63M$909.68M$859.17M$878.25M$842.66M$818.49M$749.98M$812.44M$746.09M$685.41M$659.08M$660.12M$622.63M$608.32M$556.06M$575.04M$534.94M
High Forecast$1.47B$1.44B$1.35B$1.18B$1.33B$1.26B$1.21B$1.06B$1.18B$1.08B$1.01B$921.89M$1.04B$999.01M$964.11M$910.57M$930.80M$842.66M$818.49M$749.98M$812.44M$746.09M$685.41M$659.08M$660.12M$622.63M$608.32M$556.06M$575.04M$534.94M
Low Forecast$1.29B$1.26B$1.19B$1.04B$1.17B$1.10B$1.06B$916.16M$1.08B$1.08B$1.01B$921.89M$971.32M$941.00M$846.61M$799.59M$817.36M$842.66M$818.49M$749.98M$812.44M$746.09M$685.41M$659.08M$660.12M$622.63M$608.32M$556.06M$575.04M$534.94M
# Analysts44443335149548141376686711713131599168
Surprise %-------------0.95%1.05%0.94%1.06%0.98%1.11%0.98%1.06%1.09%1.03%0.92%1.20%1.00%1.13%1.02%1.01%1.03%

Incyte's average Quarter revenue forecast for Dec 23 based on 8 analysts is $1.00B, with a low forecast of $971.32M, and a high forecast of $1.04B. INCY's average Quarter revenue forecast represents a 9.11% increase compared to the company's last Quarter revenue of $919.02M (Sep 23).

Incyte EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts44443335149548141376686711713131599168
EBITDA-------------$260.65M$193.78M$63.84M$121.08M$144.69M$258.27M$124.18M$135.63M$224.60M$186.45M$83.52M$181.70M$9.98M$320.46M$-690.38M$139.96M$162.48M
Avg Forecast$218.41M$214.11M$201.69M$175.76M$198.44M$187.49M$180.13M$158.47M$180.25M$170.36M$160.34M$125.06M$158.42M$152.25M$143.72M$113.69M$283.01M$130.38M$126.64M$103.35M$125.70M$115.44M$106.05M$79.60M$102.13M$96.33M$94.12M$-4.16B$88.97M$82.77M
High Forecast$231.48M$226.92M$213.75M$186.27M$210.32M$198.71M$190.90M$167.89M$186.52M$170.67M$160.34M$150.07M$164.64M$157.84M$152.32M$136.42M$339.61M$130.38M$126.64M$124.02M$125.70M$115.44M$106.05M$95.52M$102.13M$96.33M$94.12M$-3.32B$88.97M$82.77M
Low Forecast$203.26M$199.27M$187.70M$163.57M$184.68M$174.49M$167.64M$144.75M$170.85M$170.05M$160.34M$100.04M$153.46M$148.67M$133.76M$90.95M$226.41M$130.38M$126.64M$82.68M$125.70M$115.44M$106.05M$63.68M$102.13M$96.33M$94.12M$-4.99B$88.97M$82.77M
Surprise %-------------1.71%1.35%0.56%0.43%1.11%2.04%1.20%1.08%1.95%1.76%1.05%1.78%0.10%3.40%0.17%1.57%1.96%

8 analysts predict INCY's average Quarter EBITDA for Dec 23 to be $158.42M, with a high of $164.64M and a low of $153.46M. This is -39.22% lower than Incyte's previous annual EBITDA (Sep 23) of $260.65M.

Incyte Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts44443335149548141376686711713131599168
Net Income-------------$171.27M$203.55M$21.70M$28.46M$112.78M$161.43M$37.99M$563.85M$181.74M$149.46M$53.53M$149.85M$-15.20M$290.30M$-720.64M$111.00M$128.27M
Avg Forecast$483.19M$467.23M$410.14M$300.20M$337.52M$308.29M$283.85M$219.99M$292.82M$205.86M$146.45M$54.20M$224.90M$163.28M$136.30M$49.28M$1.18B$109.88M$122.36M$44.80M$122.42M$126.99M$120.79M$51.03M$117.50M$111.56M$105.16M$-4.34B$77.61M$96.77M
High Forecast$520.77M$503.57M$442.05M$323.55M$363.78M$332.27M$305.93M$239.83M$351.76M$221.87M$157.84M$65.04M$249.06M$193.70M$146.91M$59.13M$1.41B$109.88M$122.36M$53.76M$122.42M$126.99M$120.79M$61.23M$117.50M$111.56M$105.16M$-3.47B$77.61M$96.77M
Low Forecast$439.64M$425.11M$373.17M$273.14M$307.10M$280.50M$258.26M$183.93M$241.26M$187.30M$133.25M$43.36M$202.60M$100.85M$124.02M$39.42M$941.23M$109.88M$122.36M$35.84M$122.42M$126.99M$120.79M$40.82M$117.50M$111.56M$105.16M$-5.21B$77.61M$96.77M
Surprise %-------------1.05%1.49%0.44%0.02%1.03%1.32%0.85%4.61%1.43%1.24%1.05%1.28%-0.14%2.76%0.17%1.43%1.33%

Incyte's average Quarter net income forecast for Dec 23 is $224.90M, with a range of $202.60M to $249.06M. INCY's average Quarter net income forecast represents a 31.32% increase compared to the company's last Quarter net income of $171.27M (Sep 23).

Incyte SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts44443335149548141376686711713131599168
SG&A-------------$267.89M$283.93M$315.61M$272.82M$266.50M$253.28M$209.58M$226.20M$190.70M$168.90M$153.80M$167.00M$120.80M$118.00M$113.28M$136.18M$102.61M
Avg Forecast$350.59M$343.70M$323.75M$282.13M$318.55M$300.96M$289.14M$254.39M$289.35M$273.47M$257.38M$299.04M$254.30M$244.39M$230.71M$271.85M$471.99M$213.71M$207.58M$247.14M$206.05M$189.22M$173.83M$146.59M$167.41M$157.91M$154.28M$141.02M$145.84M$135.67M
High Forecast$371.57M$364.26M$343.12M$299.01M$337.61M$318.97M$306.44M$269.50M$299.41M$273.96M$257.38M$358.85M$264.28M$253.36M$244.51M$326.23M$566.39M$213.71M$207.58M$296.57M$206.05M$189.22M$173.83M$175.91M$167.41M$157.91M$154.28M$141.02M$145.84M$135.67M
Low Forecast$326.28M$319.87M$301.30M$262.57M$296.46M$280.10M$269.09M$232.35M$274.25M$272.97M$257.38M$239.23M$246.34M$238.65M$214.71M$217.48M$377.59M$213.71M$207.58M$197.71M$206.05M$189.22M$173.83M$117.27M$167.41M$157.91M$154.28M$141.02M$145.84M$135.67M
Surprise %-------------1.10%1.23%1.16%0.58%1.25%1.22%0.85%1.10%1.01%0.97%1.05%1.00%0.77%0.76%0.80%0.93%0.76%

Incyte's average Quarter SG&A projection for Dec 23 is $254.30M, based on 8 Wall Street analysts, with a range of $246.34M to $264.28M. The forecast indicates a -5.07% fall compared to INCY last annual SG&A of $267.89M (Sep 23).

Incyte EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts44443335149548141376686711713131599168
EPS-------------$0.76$0.91$0.10$0.13$0.51$0.73$0.17$2.55$0.82$0.68$0.24$0.68$-0.07$1.33$-3.33$0.51$0.60
Avg Forecast$2.47$2.39$2.09$1.53$1.72$1.57$1.45$1.12$1.50$1.05$0.75$0.78$1.15$0.83$0.70$0.56$0.30$0.50$0.56$0.46$0.56$0.58$0.55$0.45$0.54$0.51$0.48$0.35$0.36$0.44
High Forecast$2.66$2.57$2.26$1.65$1.86$1.70$1.56$1.22$1.80$1.13$0.81$0.79$1.27$0.99$0.75$0.60$0.32$0.50$0.56$0.46$0.56$0.58$0.55$0.45$0.54$0.51$0.48$0.35$0.36$0.44
Low Forecast$2.24$2.17$1.91$1.39$1.57$1.43$1.32$0.94$1.23$0.96$0.68$0.77$1.03$0.51$0.63$0.51$0.27$0.50$0.56$0.46$0.56$0.58$0.55$0.45$0.54$0.51$0.48$0.35$0.36$0.44
Surprise %-------------0.91%1.31%0.18%0.43%1.01%1.30%0.37%4.54%1.41%1.23%0.53%1.26%-0.14%2.76%-9.58%1.43%1.35%

According to 8 Wall Street analysts, Incyte's projected average Quarter EPS for Dec 23 is $1.15, with a low estimate of $1.03 and a high estimate of $1.27. This represents a 51.11% increase compared to INCY previous annual EPS of $0.76 (Sep 23).

Incyte Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
IONSIonis Pharmaceuticals$37.68$58.3354.80%Buy
FOLDAmicus Therapeutics$9.89$15.0051.67%Buy
DNLIDenali Therapeutics$23.22$35.0050.73%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
ACADACADIA Pharmaceuticals$17.41$25.5046.47%Buy
HRMYHarmony Biosciences$33.63$48.0042.73%Buy
AXSMAxsome Therapeutics$93.51$133.0042.23%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
ARWRArrowhead Pharmaceuticals$22.27$27.7424.56%Buy
UTHRUnited Therapeutics$379.69$440.4015.99%Buy
ARGXargenx SE$638.33$558.78-12.46%Buy

INCY Forecast FAQ

Is Incyte a good buy?

Yes, according to 21 Wall Street analysts, Incyte (INCY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 66.67% of INCY's total ratings.

What is INCY's price target?

Incyte (INCY) average price target is $90.11 with a range of $48 to $200, implying a 32.56% from its last price of $67.97. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Incyte stock go up soon?

According to Wall Street analysts' prediction for INCY stock, the company can go up by 32.56% (from the last price of $67.97 to the average price target of $90.11), up by 194.23% based on the highest stock price target, and down by -29.39% based on the lowest stock price target.

Can Incyte stock reach $100?

INCY's highest twelve months analyst stock price target of $200 supports the claim that Incyte can reach $100 in the near future.

What are Incyte's analysts' financial forecasts?

Incyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.59B (high $4.86B, low $4.25B), average EBITDA is $724.53M (high $767.82M, low $671.56M), average net income is $1.15B (high $1.24B, low $1.03B), average SG&A $1.16B (high $1.23B, low $1.08B), and average EPS is $5.87 (high $6.34, low $5.26). INCY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.13B (high $5.43B, low $4.77B), average EBITDA is $809.96M (high $858.43M, low $753.8M), average net income is $1.66B (high $1.79B, low $1.51B), average SG&A $1.3B (high $1.38B, low $1.21B), and average EPS is $8.48 (high $9.14, low $7.72).

Did the INCY's actual financial results beat the analysts' financial forecasts?

Based on Incyte's last annual report (Dec 2022), the company's revenue was $3.39B, beating the average analysts forecast of $3.29B by 3.20%. Apple's EBITDA was $631.52M, missing the average prediction of $643.38M by -1.84%. The company's net income was $340.66M, missing the average estimation of $1.45B by -76.56%. Apple's SG&A was $1B, missing the average forecast of $1.14B by -12.13%. Lastly, the company's EPS was $1.53, missing the average prediction of $1.82 by -15.96%. In terms of the last quarterly report (Sep 2023), Incyte's revenue was $919.02M, missing the average analysts' forecast of $963.63M by -4.63%. The company's EBITDA was $260.65M, beating the average prediction of $152.25M by 71.20%. Incyte's net income was $171.27M, beating the average estimation of $163.28M by 4.89%. The company's SG&A was $267.89M, beating the average forecast of $244.39M by 9.62%. Lastly, the company's EPS was $0.76, missing the average prediction of $0.834 by -8.85%